Investors of Unicycive Therapeutics Can Take Action in Securities Fraud Case

Legal Opportunity for Unicycive Shareholders

Investors who suffered financial losses related to Unicycive Therapeutics, Inc. (UNCY) now have a significant opportunity to lead a class action lawsuit targeting alleged securities fraud. The announcement comes from Glancy Prongay Wolke & Rotter LLP, a recognized law firm specializing in shareholder rights. They reveal that those who experienced losses can take decisive action against the company. The deadline for intending lead plaintiffs is set for November 2, 2026.

Allegations Against Unicycive

The foundation of this lawsuit lies in serious claims made against Unicycive Therapeutics, alleging several instances of misleading statements to investors that paint a stark picture of the company’s operational integrity. The complaint asserts that between December 29, 2025, and June 29, 2026, the company failed to disclose critical information concerning its business practices and operational challenges. Specifically, these allegations include:

1. Lack of Facility Inspection: The complaint states that Unicycive did not inspect its third-party manufacturing vendor’s facility, which raises questions about whether the vendor adhered to essential good manufacturing practices.

2. Regulatory Compliance Risks: It further alleges that the company did not provide a solid basis for believing the vendor had addressed the deficiencies cited by the FDA, thereby lacking transparency regarding the vendor's operational risks.

3. Potential Delays: The lawsuit hints at undisclosed risks that FDA evaluations might necessitate additional data from the vendor's production practices, potentially delaying the regulatory approval of the company's product, OLC.

These claims bring to light a serious disconnect between the company's positive public statements and the underlying operational issues, indicating that statements made by the company may have misled investors regarding its trading prospects.

Next Steps for Investors

For those affected, this legal action allows them to potentially recover losses. Interested shareholders are encouraged to contact Glancy Prongay Wolke & Rotter LLP for assistance in navigating the complexities of the legal system. Acting swiftly is critical, as the firm advises that investors wishing to serve as lead plaintiffs must file their motions before the specified deadline.

While Glancy Prongay Wolke & Rotter LLP is prepared to assist affected investors, shareholders should also remember that they may retain legal counsel of their choice. Importantly, those who purchased securities during the defined class period and do not wish to join the lawsuit can simply remain absent as class members. The firm has highlighted its extensive experience in securities litigation and class actions, which adds a layer of credibility to their role in assisting shareholders.

Why Trust Glancy Prongay Wolke & Rotter LLP?

With decades of experience in the industry, Glancy Prongay Wolke & Rotter LLP has established itself as a top-tier law firm for investors and consumers. The firm’s history of success in similar cases has earned it recognition in leading publications, confirming its reputation for navigating complex litigation processes effectively. Furthermore, its ranking as one of the top firms for investor recoveries solidifies its dedication to protecting shareholder interests.

For more information on how to participate in the lawsuit, shareholders are encouraged to reach out via email or phone. This opportunity presents a crucial chance for affected investors to hold Unicycive accountable for their financial losses and seek the justice and recovery they deserve.